Emergent BioSolutions traded at $8.21 this Thursday May 14th, decreasing $0.12 or 1.44 percent since the previous trading session. Looking back, over the last four weeks, Emergent BioSolutions lost 5.20 percent. Over the last 12 months, its price rose by 49.54 percent. Looking ahead, we forecast Emergent BioSolutions to be priced at 8.94 by the end of this quarter and at 8.40 in one year, according to Trading Economics global macro models projections and analysts expectations.
Emergent BioSolutions Inc. is a life sciences company focused on providing civilian and military populations with a portfolio of preparedness and response products and solutions that address accidental, deliberate and naturally occurring public health threats (PHTs). The Company is focused on five PHT categories: Chemical, Biological, Radiological, Nuclear and Explosives (CBRNE); emerging infectious diseases (EID); travel health; emerging health crises; acute/emergency care; and contract development and manufacturing (CDMO). It operates through four business units, which includes three product business units: Vaccines, Devices, Therapeutics; and one services business unit: CDMO. The Company's contract development and manufacturing service offerings cover development services, drug substance manufacturing and drug product manufacturing across the pharmaceutical and biotechnology industries as well as the United States Government (USG) and non-Governmental organizations.